Wittington Investments agreed on 7 October 2026 to acquire Boots for US$8.9 billion including assumed debt. Fairfax Financial committed up to approximately US$2.3 billion and expects to own 50% of the equity at close. The transaction is being read as a British institution passing into the hands of a long-term family owner. The disclosed terms describe something narrower: one buyer holds the operating control, a second holds half the economics, and the seller keeps part of the group. Of the US$8.9 billion headline, roughly US$4.6 billion is equity and the rest is debt that travels with the business. What exactly changed hands on 7 October? The Wittington announcement states that the total purchase consideration is US$8.9 billion, including assumed debt. Assumed debt means borrowings already sitting on the target’s balance sheet that transfer with it, so the figure is not the cash the buyers hand over. What they acquire is listed precisely: Boots’ retail operations in the UK and Ireland, the Boots Opticians business, No7 Beauty Company, and Boots’ Thailand and franchised businesses. The same document names what does not transfer. The Boots Group’s interests in Farmacias Benavides, the Mexican pharmacy chain, and in Alliance Healthcare Deutschland, the German wholesaler, remain with Sycamore Partners and Stefano Pessina and his family. The announcement puts the workforce at more than 50,000 colleagues. Boots’ own corporate site, in a note dated 28 February 2026, describes an estate of over 1,800 stores. Completion is expected in the first quarter of 2027, subject to regulatory approvals and customary closing conditions. Nothing moves before then. Who owns Boots after this closes? Most accounts of the deal name the Weston family as the buyer. Fairfax’s own release is more specific. It states that Fairfax has committed up to approximately US$2.3 billion under an equity commitment letter, and that it expects to own 50% of Boots’ equity after closing. Wittington holds operational control, and Galen Weston serves as Chair. That is an unusual division. Half the economic upside sits with a property and casualty insurance holding company. All of the operating authority sits with the family holding company. The two things that normally travel together in a control transaction have been separated by agreement. The two disclosed figures also imply a capital structure. If US$2.3 billion buys half the equity, total equity runs to roughly US$4.6 billion, which leaves approximately US$4.3 billion of the US$8.9 billion headline as assumed debt. That is arithmetic drawn from two published numbers, not a disclosed capital structure; neither release sets out the debt quantum. Several trade accounts of the transaction reported that the economic split between the two buyers had not been disclosed. The split is in Fairfax’s release. US$8.9 billion including assumed debt buys Boots’ UK and Ireland retail, Boots Opticians and No7 Beauty Company. Farmacias Benavides and Alliance Healthcare Deutschland stay with the seller. Why does No7 Beauty Company sit at the centre of this? A retailer and a brand owner are different assets, and this transaction moves both. No7 Beauty Company was created inside Walgreens Boots Alliance in April 2021 to hold the group’s owned beauty brands: No7, Liz Earle Beauty Co., Botanics, Soap & Glory, Sleek MakeUP and YourGoodSkin. Its own launch material described a business selling through more than 20,000 retail outlets across 16 markets, with No7 serums in over 16,000 stores in the United States alone. Those are the company’s figures for 2021 and no more recent equivalent has been published. The structural point survives the age of the number: No7 Beauty Company distributes well beyond the Boots estate, including through retailers that compete with Boots. So the buyer acquires a shelf and a set of brands that fight for shelf space elsewhere. Those two positions pull in opposite directions on pricing, on exclusivity and on how much space an owned brand takes from a third-party one. Whoever runs Boots after close inherits that tension rather than resolving it. No7 Beauty Company What did the seller keep, and why does it matter? This is a partial exit. Sycamore and the Pessina family retain the Mexican pharmacy chain and the German pharmaceutical wholesaler. What they sold is the consumer-facing retail estate and the owned beauty brands. What they kept is wholesale distribution and a pharmacy business in a different market. Read against the original Walgreens Boots Alliance break-up, the pattern is consistent. The pieces with a British high street attached went to a buyer that wants a British high street. The pieces that are logistics and supply went nowhere. Is the business being sold actually growing? Boots’ accounts for the twelve months to the end of August 2025 show revenue of £7.545 billion (US$9.97 billion), up 3.2%, with revenue on a comparable basis up 5.8%. Pre-tax profit reached £337 million (US$445 million), up 25%. Post-tax profit was £261 million (US$345 million), against £211 million the year before. Digital sales rose 18.3%. Sterling figures in this article are converted at GBP/USD 1.3214, the Bank of England rate for 13 October 2026. Boots attributes part of the improvement to a modernised beauty division. That attribution is the company’s own. A count of 61 brand additions during 2025, including Fenty Beauty and MAC, was reported at the time of the sale announcement; no company document setting out that figure has been published. What Boots has published is the shape of the estate. It counted 170 premium beauty halls when it opened the Westfield White City hall in March 2023, and its site currently lists more than 500 beauty brands. The asset changing hands is a growing retailer with an expanding beauty assortment, not a distressed one. Pre-tax profit grew 25% and digital sales 18.3% in the year before the sale. This is not a rescue. What happened to the stock market listing? Until this summer the expectation was a London listing. Reporting then put a sale back in play at a valuation around US$10 billion, with the Weston family’s Canadian arm and Australia’s Sigma Healthcare named among the parties in talks. The agreed consideration came in below that figure. The difference between the two outcomes is disclosure. A listed Boots would have published quarterly results, carried a visible share price and faced analysts asking why a given category received a given amount of space. A privately held Boots does none of that. Category decisions that would have been argued in public will now be argued inside a holding company. What does a Q1 2027 close mean for anyone negotiating shelf space now? Regulatory approvals remain outstanding and the parties have set completion in the first quarter of 2027. Until then the buying organisation is the one that exists today, under chief executive Alex Baldock, operating to a plan written under the current owner. A range review opened currently is therefore negotiated with one owner and executed under another. Terms agreed across that boundary carry a counterparty that changes mid-cycle. That is a documentation question, not a relationship question, and it applies to every supplier in the building. Boots in UK Does Shoppers Drug Mart change what Boots is? Wittington is the controlling shareholder of George Weston Limited, which controls Loblaw Companies Limited, which owns Shoppers Drug Mart. Loblaw acquired Shoppers in 2014 for approximately C$12.4 billion. The Wittington announcement describes Shoppers as Canada’s largest pharmacy, health and beauty business. No combination of Boots and Shoppers has been announced, and no change to No7’s Canadian distribution has been announced. What the transaction creates is a single family holding company sitting above two of the larger health-and-beauty retail estates in two developed markets, each with its own owned-brand portfolio. The group has owned and exited British retail before. Wittington acquired Selfridges in 2003 and sold the department store business roughly two decades later. Long-term ownership and permanent ownership are not the same commitment. Shoppers Drug Mart What does the structure settle, and what does it leave open? For manufacturers and contract developers, No7 Beauty Company passes to an owner whose other retail assets buy owned-brand product at scale in a second market. The sourcing question that follows is whether two owned-brand portfolios under one holding company stay separate. For brands and buyers, the counterparty at Boots is unchanged until the first quarter of 2027 and the owner above it is not. The negotiating position that matters is the one that survives a change of control. For capital, Sycamore has priced a European health-and-beauty retail estate at US$8.9 billion including debt after preparing a listing and setting it aside, and has kept the wholesale assets. A buyer willing to split control from economics with an insurer is a buyer optimising for duration rather than exit. Boots’ shelf did not change on 7 October. The clock running above it did.

Global prestige and indie beauty categories scaled into new territories faster than ever in 2025—led by a Korean cosmetics wave that reached 202 countries, with the ten largest markets absorbing 70.7% of an $11.4 billion total. Yet no African market appears in those published customs breakdowns. On 28 September 2026 Clicks Group agreed to pay R507 million, about $30.7 million, for control of ARC, a 12-store South African chain whose own K-Beauty page carries seventeen brands and whose newest arrivals are Korean. The shelf that Korea's export table does not name is the one a retail group just bought. Clicks Group budgeted R662 million for up to 50 new stores in FY2026. It agreed to pay R507 million for control of twelve. What did Clicks Group actually buy? The announcement commits Clicks Group to acquiring a further 35.3% of ARC from the retailer's founding shareholders for R507 million, lifting its holding from 25.7% to 61%. The founders retain 39%, and ARC's executive management has committed to stay until at least 2028. ARC launched in 2020 and trades from 12 stores in major shopping centres, including Sandton City and Menlyn Park, alongside an online business. The stated plan is 20 to 30 stores over the medium term, with Clicks funding the expansion. One detail in the announcement is easy to pass over. Clicks states that the transaction is uncategorised under the JSE Listings Requirements and that the announcement is voluntary. A deal that hands a listed retailer control of South Africa's leading premium beauty specialist was small enough, measured against Clicks, that nobody had to be told. Rand figures in this article are converted at 16.513 rand to the dollar, the rate of 9 October 2026. Clicks first took a minority stake in ARC in 2021, reached 25.7% in 2025, and agreed to 61% in September 2026. Why does a twelve-store chain cost as much as a year of new stores? Clicks Group reported FY2025 turnover of R47.8 billion (about $2.90 billion), of which retail turnover was R37.6 billion. Beauty and personal care accounted for R12.2 billion, up 7.3%, and front shop health for R9.6 billion, up 7.5%. The group operated over 990 Clicks stores and a pharmacy network of 780, within a group total of 1,060 stores that also includes The Body Shop and Sorbet. The medium-term target is 1,200 stores. For FY2026 the group allocated R662 million in capital expenditure for up to 50 new stores and pharmacies and up to 90 refurbishments. Set R507 million against R662 million. Three-quarters of a year's entire new-store budget buys control of twelve doors. Clicks is not buying floor space, which it can build. It is buying a price tier it does not operate in. Premium beauty — the band above mass, sold with assisted service and with brands controlling which doors they appear in — is a market Clicks puts at more than R6 billion a year (about $363 million), and that figure is the company's own. Prestige brands decide their own distribution. A mass retailer cannot simply list them. Buying the retailer that already carries them is the faster route, and the price reflects that rather than the twelve leases. Clicks Group What is actually on ARC's shelves? ARC's K-Beauty page, read directly, carries seventeen brands: Mixsoon, COSRX, Beauty of Joseon, Biodance, Barulab, Haruharu Wonder, Axis-Y, SKIN1004, Laneige, Medicube, Erborian, Innisfree, Purito Seoul, TIRTIR, Anua, Tocobo and VT Cosmetics. Listed prices run from R159 (about $10) to R1,240 (about $75), with most items between R359 and R699, or roughly $22 to $42. Two of those names, VT Cosmetics and Tocobo, also appear in the site's newest-arrivals brand list, which places Korean brands among the most recent additions rather than the legacy range. The page presents the range as a second wave of K-beauty and emphasises fermented ingredients, gentle exfoliants and barrier formulations. That is retailer copy, not a product claim, but it is informative about positioning: ARC merchandises these brands as current prestige, not as a discount curiosity, and the price band supports that. The label itself is worth examining. Erborian sits inside ARC's K-Beauty edit and is a French-Korean brand that L'Occitane acquired in 2012. Laneige and Innisfree are Amorepacific brands. The shelf is organised by a retailer's idea of a category, not by corporate nationality, which means the shelf and the export statistic are counting different things from the start. More broadly, K-beauty functions here as the vanguard of modern prestige curation—an agile, digitally native wave rewriting how traditional retail tiers fill their floors. ARC groups seventeen brands under one K-Beauty label. Korea's published export league table names no African market. Is 'Africa's biggest beauty store' a fact or a description? The phrase travels with the deal. ARC's Sandton City outlet is described as the largest standalone beauty store on the African continent, and that description originates with the parties and is repeated across the reporting. There is no independent register of African beauty retail floorspace against which it can be tested, so it belongs in the article as a description the companies chose rather than as a measured fact. What is testable sits alongside it and is more useful: twelve stores, named shopping centres, a 20-to-30-store target, R507 million for 35.3% of the equity, and a controlling position that does not yet exist in law. ARC's Sandton City outlet What does Clicks get that it cannot build? The commercial plumbing between the two businesses predates the equity. ARC has been an affinity partner of the Clicks ClubCard loyalty programme since 2021, and Clicks stores already serve as collection points for ARC orders. The announcement reports that spending at Clicks by registered ARC customers rose 16% over the past year to R836 million, about $50.6 million. That number repays attention. It measures what ARC's customers spend inside Clicks. It is not ARC's turnover, which has not been disclosed, and the announcement does not claim it is. Clicks is describing the value of a customer base to its own tills, which is a coherent reason to buy control and a different thing from buying a profitable retailer. Clicks Group What changes for a Korean brand on that shelf? Before approval, ARC is an independent specialist with twelve doors setting its own range. After it, range decisions sit inside a group with over 990 stores, a 1,200-store target and a national loyalty database. The announced expansion takes the premium format from twelve doors to between twenty and thirty, which roughly doubles or triples the shelf a listed brand is competing for. The counterweight is that the buyer now reports into a group running a R12.2 billion mass beauty business. Range overlap between the two formats becomes a group question rather than a negotiation with a specialist buyer. The founders' retained 39% and the management commitment through 2028 are the structures both sides put in place to hold the curation steady, and both have dates attached to them. Why is the deal not finished? The transaction is conditional on competition authority approval, and Clicks states that it will take effect on the first day of the month following that approval. No approval has been reported. Until it comes, Clicks holds 25.7% and ARC's buying decisions remain its own. Any brand building a South African plan around a twenty-to-thirty-store rollout is building it against a conditional event with no published timetable. The shelf expansion is funded, announced and not yet permitted. ARC's Sandton City outlet Where does this leave the three sides of the trade? For manufacturers and ODM operators — the contract developers and manufacturers who produce finished goods for brand owners — demand that never appears in a national export table still consumes capacity. Order books show where volume is going earlier than customs summaries do, and the gap between the two is where unserved markets sit. For brand owners and buyers, the question in South Africa has changed shape. It is no longer which specialist retailer to court, but which group owns the specialist and what else that group sells. Door counts move with ownership, and so do the terms attached to them. For regulators and investors, a R507 million transaction that nobody was required to announce has changed who controls South Africa's leading premium beauty specialist. Materiality thresholds measure the acquirer. They do not measure the shelf. The shelf was built before anyone counted it. The counting comes afterwards.

Walmart’s US site lists MONDAY Haircare shampoo at $5.97 for 354 millilitres. The brand takes no direct orders anywhere: its own website has no checkout, only a stockist finder. It does own the plant that fills the bottle. Most beauty companies treat the factory as the thing to rent and the customer relationship as the thing to keep. This company inverted both, and the price on the shelf is what the inversion pays for. A 354-millilitre shampoo at $5.97 and a 798-millilitre bottle at $12.97 sit in the same range, under the same brand. What does $5.97 actually buy on a mass shelf? Walmart’s brand page lists a 354-millilitre Volume Shampoo at $5.97, a Smooth Shampoo and Conditioner pair at the same price, a 798-millilitre Moisture Shampoo at $12.97 and a 200-millilitre dry shampoo at $8.99. Texturising mousse, heat protectant, hairspray and a deep moisture mask all sit at $6.97. Nothing on the page clears $18. The same shape holds in other currencies. The Boots listing in the UK shows a 350-millilitre shampoo at £3.33, marked down from £5.00. In Australia the brand opened at Coles at $10 a bottle. The range has widened since launch into body wash, styling and treatments, and the ceiling has not moved with it. A band this tight across four categories and three currencies is not a promotional posture. It is a constraint the business accepted before it designed anything. MONDAY Haircare VOLUME Shampoo with Hydrolyzed Collagen & Macadamia Oil at Walmart Why has the entry price moved down rather than up? Reporting in 2022 put the range at $7.99 to $15.99, with a 12-ounce bottle at $8. The current entry price at Walmart is below that in nominal terms, four years and one inflationary cycle later, while the assortment has grown. The company’s own explanation has been consistent: vertical integration and quality control are what allow it to hit mass price points and still protect margin. That is a statement about structure, not about procurement. A buyer who negotiates well gets a better cost on a given order. A business that owns the line changes what the cost is made of. The difference shows up when inputs move. A brand buying from a contract manufacturer renegotiates, absorbs, or reprices. A brand that owns the plant has fewer counterparties to renegotiate with and a longer horizon over which to absorb. The flat shelf price is the visible end of that. What changed when the brand stopped renting its factory? It started the way most do, with third-party manufacturing. The parent’s stated pattern is to outsource a brand at launch and bring production in-house once the brand proves itself. For this one that meant a 27,000-square-metre innovation and development facility in China with capacity above 100 million bottles a year, roughly eight a minute, with a former L’Oréal head formulator leading research. Those capacity figures are the company’s own. Two things disappear when a brand crosses that line. One is the manufacturer’s margin. The other, less discussed, is the manufacturer’s calendar. Short lots, reformulations, a pack change for one retailer, a texture variant for one market — these stop being commercial negotiations and become internal scheduling. Speed to shelf is mostly a scheduling problem. What arrives in their place is fixed cost. A hundred million bottles of annual capacity is a utilisation problem before it is an advantage, and it has to be filled from somewhere. The rest of this company’s behaviour follows from that sentence. The company owns the formula and the line. It owns nothing on the far side of the shelf, including the shopper. In what order does this company take a country? The brand was developed in 2019, took its first retail listing in New Zealand grocery at the end of that year, and launched in February 2020. The company says it held more than a quarter of the haircare category at that grocery group within 20 days. Its claim to have outsold the market-leading shampoo brand after moving to Coles in Australia has been retold with different timeframes — six weeks, seven weeks, three months — and all of those figures are the company’s own. The Australian sequence is the part worth reading closely. Coles first, a grocery chain. Big W next, earlier in 2026, a general merchandiser. Then 280 Kmart stores in early October 2026, a discount variety chain, with a six-item range: moisture shampoo and conditioner, dry shampoo, leave-in conditioner, deep moisture mask, repair oil and heat protectant spray. That took the Australian footprint past 1,200 stores. Every step in that order is a wider door at a lower average basket. Brands usually run this in reverse, starting narrow and premium and defending the price as they widen. Starting at grocery means the opening price is set by the hardest buyer in the market, and every subsequent door has to accept it rather than set it. Coles supermarket in Australia. Why does a beauty brand refuse to sell direct? There is no direct-to-consumer business, and that is deliberate rather than unfinished. The brand’s site carries product pages, an ingredient explainer, an FAQ and a regional selector for seven markets, and its only purchase route is a stockist locator. The founder’s stated reasoning is that the company partners with mass retailers because they run retail better than it could. The arithmetic supports her. Direct selling adds fulfilment, returns, payments and customer service, and above all customer acquisition cost. On a $5.97 unit, acquisition cost is the line that ends the business. Refusing the channel also removes the oldest argument in the buyer’s office, which is the brand’s own site undercutting the shelf. The saving is real and so is the price of it. Every shopper who buys the product is the retailer’s shopper. That is the part the model cannot fix, and it comes back at the end. What does the company do once it has the shelf? It runs the same entry again with a different name. In July 2024 it launched being, a second haircare brand, exclusively at Walmart at under $7, having come in through Walmart Start, the retailer’s own programme for emerging beauty brands. The line is organised by hair type rather than by concern, spanning the 2A to 4C range, and the company has described it as the retailer’s number one new shampoo and conditioner brand. In February 2026 that brand widened into Target stores nationwide with five additions at $7.99 — two mousses, a detangling milk, a smoothie and a moisture mousse — alongside listings at Ulta Beauty, Amazon and CVS. Nineteen months separate the exclusive launch at one chain and the national rollout at its closest competitor. Read as a pattern rather than two announcements, this is a company using a retailer’s own emerging-brand pipeline as a product development channel, then taking the proven result across the street. The second brand did not need to find a shelf. It was built against one. One retailer at a time, each entry narrow and exclusive before it widens. The pattern repeats with each new brand. How many brands is this business actually running? More than the haircare label suggests. The parent’s consumer division has launched nappies, supplements, collagen, deodorant, bodycare and fragrance under separate names, beginning with a nappy brand in 2017 that became one of the largest in its category worldwide. The founder has added a naturals line, a fragrance house, a Gen Alpha bodycare brand that opened at Ulta Beauty and moved into Target, and a hairstylist-led brand that launched into Target nationwide. The stated plan has been ten brands by 2026. The headcount makes the point sharper. The consumer division runs on roughly 250 people, of whom about fifteen work on the flagship haircare brand. The group employs more than five thousand across nearly thirty offices, one of which is in Bentonville, Arkansas, where Walmart is headquartered. The business was self-funded apart from a small family loan at the start. Fifteen people on a brand that holds tens of thousands of doors is only possible if the brand is not the asset. The asset is the line behind it and the buyer relationships in front of it, and both of those are reusable. That is how a factory with a hundred million bottles of capacity gets filled. A vibrant collage showcases "being," a haircare brand, highlighting diverse products for different hair types with messages of confidence and individuality. Where does the model run out? At the shelf edge, in two directions. The first is informational. With no direct channel, the company has no transaction of its own to count, no price test it can run alone and no record of who buys. Its own site currently lists 31 countries while company figures have put the market count higher, and there is no internal order book that settles the difference. A business that cannot count its customers is reading its market through its buyers. The second limit is structural, and it is the sharper one. Owning the plant is a durable advantage against brands that rent one. It is not an advantage against a retailer’s own line, which also controls its supply, carries no brand marketing to fund, and sits on the same fixture with the shelf position decided in-house. Every chain that takes this brand for its opening price point already knows how to build the alternative, and now has a demonstrated price to build it against. The factory bought the price. The price bought the shelf. The shelf still belongs to someone else. Vibrant and playful images showcase a variety of Monday shampoo and haircare products, emphasizing their soft pink packaging.

L'Oréal opened a Dr.G storefront on TikTok Shop in the United States in October 2026, and the trade read it as a conglomerate skipping retail in favour of social commerce. Two facts complicate that reading. Ulta Beauty opened its own TikTok Shop in March 2026 and Sephora began a pilot there on 19 September, so the platform is not a way around those retailers — they are standing in it. And Dr.G had been selling to Americans for eleven months already, on Amazon. The conventional sequence runs retailer, doors, then online. Dr.G ran Amazon, then TikTok Shop, then nothing announced. What exactly opened? Seven products, drawn from the R.E.D and Black Snail lines, and five bundles that exist only on the platform. Single items run from $25.99 to $44.99. The bundles run from $29.99 to $89.99 and carry savings the company puts at up to 63 percent against full retail. Around it sits what L'Oréal calls a 360-degree campaign: creator partnerships, out-of-home advertising, influencer activations, launch events in New York and Los Angeles. Tina Fair, who runs North America for the Consumer Products Division, framed the ambition as reaching every K-beauty consumer in America. Dr Gun-Young Ahn, the dermatologist who founded the brand in 2003, supplied the other half of the announcement. No store. No door count. No date for either. Dr.G, ⓒinhoocho.com Is this actually a channel-first launch? Not quite, and the order matters more than the headline does. Dr.G entered the United States in November 2025, through Amazon. TikTok Shop is the second online channel, arriving eleven months behind the first. The retailers are the other complication. Ulta Beauty opened on TikTok Shop in March 2026, describing itself as the first US specialty beauty retailer on the platform, with more than fifteen brands and twenty-five-plus exclusive bundles. Sephora followed on 19 September 2026 with a pilot it calls the Drop Shop, where products appear on TikTok first and reach Sephora.com and selected stores afterwards. So the picture is not a brand going around its retail partners. It is a brand and its retail partners arriving in the same room by different doors, seven months apart. Who owns Dr.G, and for how long? Dr Gun Young Ahn founded Dr.G in Seoul in 2003 and built it inside Gowoonsesang Cosmetics. In July 2018 Gowoonsesang sold 51 percent of the brand to Mibelle, the beauty arm of the Swiss retail group Migros. Gowoonsesang's revenue the year before that was 28.7 billion won — about $25 million at the rate reported at the time — on 2.1 billion won of operating profit, with more than half of sales already coming from outside Korea. The reason given then was China. In December 2024 L'Oréal agreed to buy Gowoonsesang from Migros, price undisclosed, placing Dr.G in the Consumer Products Division, which is the mass-market half of the group rather than the luxury half. Kantar Korea data cited in that announcement put the brand consistently among the top three mass and dermocosmetic skincare brands in the country. Founder-owned until July 2018, Swiss-controlled until December 2024, French-owned since. The country on the label never changed. Which means the brand being introduced to Americans as Korea's most popular skincare brand has not been Korean-controlled for eight years. The marketing is accurate about the country. It says nothing about the flag on the cap table. The current ranking claim deserves the same care. Dr.G says it is number one in Korea by penetration, citing Worldpanel by Numerator for a period running from March 2020 to March 2025 — a window that closed about eighteen months before the storefront opened. What do the prices say about the job this storefront is doing? An $89.99 bundle at up to 63 percent off implies a full-price reference somewhere near $240. That is not a prestige posture. It is a volume posture, and it tells you which division bought the brand. Single products run $25.99 to $44.99. Bundles run $29.99 to $89.99, at savings the company puts at up to 63 percent. On TikTok Shop the unit of sale is frequently the bundle rather than the item, because a creator demonstrating three steps sells three steps. The bundle is also where the discount hides, which keeps the single-item price intact for whatever shelf comes later. A brand that cuts the price of its hero product on day one has to explain that number to a buyer in year two. Seven products is a narrow range. Enough to run a routine on camera, not enough to confuse one. Why does a conglomerate buy a brand and then discount it? Because the discount buys information. NielsenIQ measured global K-beauty value sales up 53 percent year on year as of July 2026, and a group that owns a Korean dermatologist brand wants a position inside that number. What it does not own is American demand data for this brand at this price. A door costs a forecast, a planogram — the retailer's shelf map, fixed months ahead — and a commitment to fill it. A storefront costs a creator brief. One of those is reversible in a week. Then there is what a retailer asks for. Buyers at Sephora and Ulta want sell-through evidence, meaning the rate at which stock actually leaves the shelf. Eleven months of Amazon plus a quarter of TikTok Shop produces exactly that, in a form L'Oréal owns rather than one a retailer hands back. What does a Korean brand that grew up on this platform look like? Different in the accounts, mostly. Between January and August 2025, TikTok Shop's beauty category turned over $1.4 billion across 84.6 million items, with monthly sales passing $200 million at the summer peak. Medicube took $44.3 million of that, second only to Tarte at $53.6 million. Dr. Melaxin took $24.9 million. The hashtag #koreanskincare accounted for $40.1 million on its own. Those Korean brands were not placed on the platform. They were built on it, with unit economics that assumed creator commission, bundle pricing and a return rate from the first day. Dr.G arrives with the opposite inheritance — a cost structure designed for Korean retail, and a parent whose reflex is a shelf. The two get reconciled eventually. It takes a year and a different P&L. Dr.G introduces its skincare innovations in a vibrant lab setting, showcasing products and expertise. Does any of this still count as skipping retail? Partly. There is no announced US store deal, and for a brand inside the world's largest beauty group that is an absence rather than an oversight. But the thing being skipped is not the retailer. It is the retailer's calendar. A beauty reset happens twice a year and a listing decision gets made six to nine months ahead of it; a storefront opens when the creative is ready. L'Oréal did not choose social commerce over Sephora. It chose October over spring. What stays open is the question of what the storefront is for. A permanent channel and a twelve-month audition look identical from outside, and they are priced identically too. What should other brands take from the order of the steps? That the sequence is itself the strategy, and that it runs in one direction. Amazon first, because search demand and reviews are the cheapest proof a brand can buy. Then a social storefront, because discovery and bundle economics test something different. Then the shelf conversation, held with numbers the brand generated rather than numbers a retailer quotes back at it. Reverse the order and you give away the record. Sell through a retailer first and the retailer owns the sell-through, the shopper and the renegotiation. Which is the whole reason distributors and platforms have spent 2026 buying their way downstream. None of that requires L'Oréal's balance sheet. It requires patience with the order. Dr.G, ⓒL'Oréal Where does this leave the three parties? Manufacturers and ODM suppliers — the contract developers who formulate and fill for other people's labels. Bundles mean set packaging, short runs and forecasts that move with a creator's week. Quote the flexibility, not only the unit. Brands and the buyers who stock them. A platform launch is a demand test wearing the clothes of a launch. Price a first order as a test, and read a competitor's storefront as research rather than as a position taken. Investors. The number to watch is not TikTok Shop revenue, which nobody discloses cleanly. It is whether a US retail agreement appears, and how long after November 2025 it takes. Eleven months in, there is nothing. The shelf did not get skipped. It got postponed, and somebody is counting.

Mary Kay put three skincare products on sale in 40 markets on 5 October 2026 and described all three as Korea-made. The announcement went out in fourteen languages. It names the actives — PDRN, snail mucin, collagen peptides — and it names the executive who signed off. It does not name the company that made any of them, and it does not give a price in a single one of those markets. The country is printed on the label. The maker is not. Five fields in the 5 October announcement. Country, actives and markets are filled in. Manufacturer and price are blank. What exactly launched? The collection is called the K-Beauty Texture Edit, sold on Mary Kay's site and through its Independent Beauty Consultants, while supplies last. Three products: a Melt-In Cleansing Balm built on PDRN — purified salmon DNA fragments — with rice bran oil and vitamin E; Snail Gel Face Patches with snail mucin, niacinamide, licorice extract and several forms of hyaluronic acid; and a Collagen Moisturizing Gel with collagen peptides, niacinamide and squalane, finished for what the company calls a glass-skin-inspired glow. Dr Lucy Gildea, Mary Kay's chief brand and scientific officer, is the quoted executive. The collection arrived a month after the company launched what it describes as its largest consumer-facing global platform. No prices anywhere. No door count, because there are no doors. DR. LUCY GILDEA, CHIEF INNOVATION OFFICER, PRODUCT AND SCIENCE What is the word Korea-made actually doing? Working as a credential. Not as a disclosure. Origin marks earn that status slowly and only in a few categories — Swiss for movements, Italian for leather, German for machine tools. The mark survives because buyers have learned it predicts something about the object, and once they have, a company can put it on pack and get paid for it without explaining anything further. That is what happened here. A sixty-three-year-old American direct seller decided that printing Korea-made on three skincare products was worth more than printing nothing, in 40 markets at once, without feeling any need to say which Korean company was involved. Korean manufacturing spent twenty years building that shorthand. This is the first time it has been visible as a licence somebody else can pick up for free. So who made it? The announcement does not say, and that silence is standard rather than suspicious. Contract manufacturing agreements normally bar the supplier from claiming the client, and brands rarely volunteer a factory name on a launch. What can be read off the formulations is the capability required. PDRN at cosmetic grade, a balm-to-oil-to-milk phase change that has to survive shipping into 40 markets with different climate zones, hydrogel patch casting, and a collagen-peptide gel with a specific optical finish. That is a list of things Korean ODM houses do routinely and most of the rest of the world's contract manufacturers do not do well. Which is the shape of the whole arrangement. The capability is Korean, the credential is Korean, and the brand equity accrues in Texas. Three Korean capabilities feed one label, and the label is the only thing that crosses into Texas. Why would a direct seller want this now? Because direct selling has a distribution problem that K-beauty solves and a product problem that K-beauty also solves. The distribution problem is recruitment. A consultant's pitch needs something new often enough to justify the conversation, and a category the customer has already heard of from somewhere else does that work for free. The product problem is that textures sell themselves in a demonstration. A balm that melts, a patch that cools, a gel that goes glassy — these are things a consultant can show at a kitchen table, which is the actual sales channel. Notice the collection is named for texture, not for an ingredient or a benefit. That is not a marketing accident. What does 40 markets mean that 400 doors does not? Retail distribution is geographic in a lumpy way. A brand lands 400 doors in one country, then spends two years and a separate regulatory file getting into the next. Direct selling is already everywhere it is going to be, and a new product reaches all of it on the same morning. Mary Kay has been operating for more than sixty years and is in 40 markets. Euromonitor has ranked it the world's number one direct-selling brand of skincare and colour cosmetics for four consecutive years. That network is the asset, and the asset was built long before anybody in Dallas had heard of snail mucin. A Korean indie brand with a better cleansing balm cannot buy that reach. It can be manufactured into it. Direct selling reaches all 40 markets on launch morning. A retail rollout is still in single figures at year one. Is while supplies last a commitment or a test? A test, and the phrasing is the tell. A limited run means a finite purchase order, no repeat commitment and no reformulation obligation. If it sells, the second order is the real one and the terms get renegotiated from a position the supplier will like less. For whoever is filling these, that is the familiar trap in a new coat. The opening order on a 40-market launch from a company this size is a serious number. It is also potentially the only number, and a supplier that prices the tooling and the formulation work across an assumed second run is lending against a hypothesis it does not control. Does this help Korean brands or compete with them? Both, unevenly, and the split depends on where the customer lives. In markets with real K-beauty retail — the United States, the United Kingdom, France — this is mostly validation. A shopper who tries a Mary Kay cleansing balm and likes the format is one search away from the Korean brands that invented it, and those brands are on a shelf nearby. In the rest of the 40 it is substitution. A consumer in a market where no Korean brand has a distributor, no listing and no local-language regulatory file can now buy PDRN from a consultant who lives down the road. That demand gets met, permanently, by somebody else. The lesson Korean brands paid to teach is being monetised in the territories where they never showed up. Mary Kay introduces its new line of K-beauty products, celebrated by a diverse group showcasing vibrant skincare solutions. What should a Korean ODM supplier take from this? That the country credential is now worth more than the company name, and that this is a problem disguised as a compliment. Korean contract manufacturers have spent two decades becoming the reason a product is good while remaining the part of the label nobody reads. The stronger Korea-made gets as a mark, the less any individual supplier can charge for being the one behind it, because the client is buying the country. The defence is not publicity. It is the thing a client cannot source elsewhere at the same speed: a proprietary delivery system, a stability dossier that saves nine months, a regulatory file that clears 40 markets without rework. Capability that is specific is priced specifically. Capability that reads as generically Korean is priced generically. Where does this leave the three parties? Manufacturers and ODM suppliers. The win is real revenue at real scale. The risk is becoming interchangeable inside a claim the client owns. Push for named technologies and multi-year terms, and price a first order as a first order. Brands and the buyers who stock them. Korea-made is no longer a Korean brand's exclusive advantage. In 40 markets it now belongs to a company in Texas, and the differentiator left is the brand itself — the thing a label cannot be made to say. Investors. Watch for the second order. A repeat of this collection, or a permanent line, would mean a global direct seller has decided Korean manufacturing is infrastructure rather than a seasonal theme. That is a bigger signal than the launch. Korea built the credential. Somebody else is printing it.

Proya opens in 400 Ulta Beauty doors in November, plus Ulta.com and the app, with two skincare lines. The group did $1.5 billion in revenue in 2025 and has been China's largest beauty company by revenue three years running. Ulta is also where K-beauty built the $2 billion it sold in the United States last year. The surprise isn't that a Chinese brand turned up on that shelf. It's that this is the third one since September. Proya takes 400 Ulta doors in November. K-beauty sold $2 billion in the United States in 2025, and Ulta is where it got there. What exactly did Proya buy? The partnership was announced on 19 August 2026 and starts in November. Two collections go in — Advanced Firming and Original Repair — across 400 Ulta stores, Ulta.com and the Ulta app. Yuli Cai, who runs Proya's overseas business, framed it in the announcement this way: "Global expansion today is about far more than simply entering a new market. It means earning a lasting place in consumers' daily skincare routines." November is not an accident. A launch in the first half of that month puts a new brand on shelf with full stock through Black Friday and the gifting window, which is the one period of the year when an unfamiliar name gets picked up on impulse by somebody buying for somebody else. No investment figure, no margin terms, no exclusivity detail. As usual. Proya headquarters in China. Is this actually a first? It is reported as one — the first prestige Chinese skincare brand to land a full omnichannel partnership with Ulta. Read that again and count the conditions. Prestige. Skincare. Full omnichannel. Three qualifiers before the word first does any work. Strip them and the picture changes. Flower Knows went into 450 Ulta doors on 20 September 2026, fifty more than Proya is getting, with five launches scheduled through to 30 January 2027. Florasis was reported entering in the same stretch. Both are makeup rather than skincare, and the Flower Knows arrangement has an end date on it, which is what the qualifiers are doing. So Proya is not the first Chinese brand on an Ulta shelf. It is the first with a permanent skincare position and a full channel set. That is still a meaningful distinction, and it is a narrower one than the headline carries. Three conditions sit in front of the word first: prestige, skincare, and full omnichannel. How big is Proya, and how big is C-beauty in America? Proya Cosmetics took $1.5 billion in revenue in 2025 and has topped the Chinese beauty industry by revenue for three consecutive years. Flower Knows, the makeup brand already in Ulta doors, did $252.4 million in the same year. These are not small companies. North America is now C-beauty's fastest-growing region, accounting for 14.9 percent of its global product market in 2025. Growing fastest from a small base is still growing fastest from a small base, and trade coverage of the Proya deal is careful to say C-beauty remains niche in the United States. Set that beside $2 billion of K-beauty sold in America in 2025 and the asymmetry is the first thing worth noticing. One of these is a category. The other is a handful of brands with good balance sheets. Why does the shelf matter more than the sales number? Because Ulta is not a neutral surface. It is the specific retailer through which Korean brands converted viral attention into physical distribution, and the machinery it built to do that is now available to anyone. Look at the plumbing. In March 2026 a single marketplace partner added 17 Korean brands to Ulta's platform at once, twelve immediately and five more by May, naming Cosnori, Vidivici, Yadah, Menokin, Hwarang and others most American shoppers had never heard of. The partner's chief executive put the problem plainly in the announcement: brands that go viral in Seoul can take years to reach the US. Her fix was a marketplace listing in as little as nine weeks against at least nine months for a traditional in-store launch. That pipeline was built for Korean velocity. It does not check passports. PROYA Does a 400-door launch threaten a $2 billion category? Not on these numbers, and saying otherwise would be a disservice to anyone planning against it. Four hundred doors is a test footprint. Ulta runs well over a thousand stores. Two skincare collections from one brand do not move a category that took a decade to build. What it does threaten is narrower and more specific: the assumption that Asian skincare on an American prestige shelf means Korean skincare. That assumption has been free for Korean brands for years. It stops being free the moment a shopper can compare a Chinese firming serum with a Korean one in the same bay, at a similar price, with the same retailer's name behind both. Share of shelf is not share of market. It is the thing that decides share of market two years out. China's largest beauty group enters a market where its whole category is still described as niche. What transfers from the K-beauty playbook, and what does not? The transferable part is everything structural. Marketplace-first listings, a hero SKU, a retailer willing to run an Asian-origin section, a shopper who has already been taught that a ten-step routine is not strange. Korean brands paid for that education in marketing spend over a decade. It is now ambient, and Proya inherits it without a line item. The part that does not transfer is the cultural tailwind. K-beauty arrived in America attached to music, television and a broadly warm national brand. C-beauty arrives into a political environment where Chinese consumer goods carry a different set of associations, and into a tariff regime that has been anything but stable. Proya's two collections will be judged on texture and price in a way Korean serums briefly were not. What should a Korean brand watch in the first ninety days? Three things, and none of them is the launch coverage. Whether the 400 doors become 800 at the spring reset, which is the only real signal of sell-through. Whether Ulta gives the collections a dedicated fixture or folds them into general skincare, because the fixture is where margin and intent live. And whether Proya's price points land above or below the Korean brands in the same bay. That last one decides the shape of the fight. Above, and it is a premium positioning play that leaves the Korean mid-tier alone. Below, and it is the same undercutting pattern Korean brands have already watched play out in Southeast Asia. PROYA Where does this leave the three parties? Manufacturers and ODM suppliers. A Chinese brand scaling in American prestige retail is a customer, not only a competitor. Korean ODM houses already make for global brands across every origin, and the question for them is commercial rather than patriotic: whether to quote the work. Brands and the buyers who stock them. The Asian-origin section at a US retailer has stopped being a Korean section. Anyone who has been selling on origin rather than on formulation now has to sell on formulation. Investors. Watch door counts at the spring reset, not launch press releases. A brand that holds 400 doors into April has proven something. A brand that announces 400 doors in August has proven it can sign a contract. Korea spent ten years teaching American shoppers to buy Asian skincare. The lesson took.

DUA by Augustinus Bader opened what it calls its first permanent store in Paris in early October 2026. The space runs to about 20 square metres, which is roughly 215 square feet. It sits beside the Augustinus Bader boutique that has occupied the Palais-Royal since March 2018, and the pop-up it replaces was at that same address. The brand sells three products. A brand launched in November 2025, three products priced €38 to €78, and a permanent address of about 20 square metres. What actually opened? DUA launched in November 2025, a collaboration between Dua Lipa and Professor Augustinus Bader, with Charles Rosier — co-founder and chief executive of Augustinus Bader — running the company side. Three products: a Balancing Cream Cleanser at €38, a Supercharged Glow Complex at €78 and a Renewal Cream at €72. They run on TFC5, a gentler version of the TFC8 complex in the parent brand's own line. Dua Lipa is chief creative officer, and by the company's account her involvement runs from formulation through to art direction rather than stopping at the campaign. The store was reported on 5 October 2026. Roughly 20 square metres, adjacent to the Augustinus Bader boutique in the Palais-Royal, with the United States named as a possible next market. DUA, ⓒDUAbyAB.com Whose address is it? The Augustinus Bader store at Galerie de Beaujolais opened on 13 March 2018. DUA's Paris pop-up ran at that same address, through to 7 June 2026. The permanent space is next door to it. So the sequence runs: pop-up inside the parent's Paris store, then a permanent room beside the parent's Paris store. Between those two states, what changed was the lease. The location did not change, the footfall did not change, and the catchment did not change. That is not a criticism. Borrowing a partner's address is the cheapest way in existence to find out whether a young brand can hold physical retail, and doing it next to the scientist whose technology you license is smarter still. It is just not what the phrase first permanent store usually conjures. The pop-up and the permanent room share a doorway. Between the two, what changed was the lease. What does 20 square metres actually buy? Twenty square metres is a generous lift lobby. It is a fraction of one Sephora bay. What it buys is an address with no expiry date, a fixed staff position and the right to use the word permanent in a press release. For a brand with three SKUs the floor plan was never the constraint — three products do not fill a room, however small the room. The constraint is whether anybody walks in. Read it as a finance decision and it makes complete sense: a conversion of marketing spend into fixed cost, at the smallest increment anybody could reasonably call a store. Dua Lipa’s Brand With Augustinus Bader Gets First Permanent Boutique Can three products hold a shop? Three SKUs between €38 and €78 means a customer who buys the entire line spends under €190. A staffed space, even a small one, needs either very high conversion or a job other than selling. The job is proof. A permanent address makes a celebrity brand legible as a company rather than a drop, and it does that for a buyer at a department store as much as for a shopper on the street. The useful thing to take from it is that the credential turns out to be cheap. It can be 20 square metres. It can be borrowed. Why compare a German luxury brand with Korean retail? On paper, there is no direct connection. Dua by Augustinus Bader—a skincare line launched in collaboration with global pop star Dua Lipa—is a German science-backed brand based in London. It has no Korean manufacturing links, OEM contracts, or local acquisition history. For a publication tracking Korean cosmetics, highlighting a Western celebrity brand might seem like a detour. However, looking at the brand’s latest retail expansion side-by-side with recent K-beauty moves highlights two completely different strategies for winning global beauty consumers: While Augustinus Bader and Dua Lipa opened a dedicated, permanent Paris storefront for their younger diffusion line (Dua by Augustinus Bader) to build long-term equity, South Korea's retail giant Shinsegae took the opposite approach in New York. Shinsegae launched Hyperground at Hudson Yards—a temporary pop-up featuring 30 trending K-beauty and lifestyle brands like Mixsoon, Hince, and Sungboon Editor. Rather than committing to a permanent storefront, Shinsegae used the pop-up as a low-risk test lab to gather consumer data and gauge U.S. demand before making long-term investments. Both moves happened in the same season, but they reveal two distinct philosophies: building a permanent brand sanctuary versus using temporary retail to capture viral momentum. A three-product brand went permanent at 20 square metres. A thirty-brand platform runs to 31 December with nothing permanent announced. Which one is taking more risk? On the face of it the permanent store is the commitment and the pop-up is the hedge. Put the two side by side and that reading gets harder to hold. Neither company published a cost, so nobody outside them knows. What is published is the scale. DUA's commitment is 20 square metres next to a partner who was already paying for the location, carrying three products. Shinsegae's is a Hudson Yards footprint for three months, carrying the inventory and staffing of about 30 brands. One of those is a lease change. The other is a quarter of trading. Is permanence still the milestone the industry treats it as? The received ladder goes pop-up, then shop-in-shop, then permanent store, then flagship, with each rung read as a promotion. These two cases suggest the ladder has flattened from both ends. The permanent store got small enough to be a formality. The pop-up got big enough to be a business. For anyone running a Korean brand or a Korean retail platform, the practical consequence is to stop reading we opened a permanent store as a statement about scale, and to ask the two questions that actually carry information: how many square metres, and whose name is on the lease. DUA, ⓒDUAbyAB.com Where does this leave the three parties? Manufacturers and ODM suppliers. A three-SKU brand with a permanent Paris address still orders like a three-SKU brand. Retail prestige and order volume have come apart, and a store opening is not a demand forecast. Brands and retailers. The cheapest route to a permanent address runs through a partner who already holds one. Korean brands with European distributors sitting on leases have that option available and largely do not use it. Investors and buyers. Read the square metres, not the adjective. A permanent store used to mean a company had arrived somewhere. This one means it stopped paying by the month.

Five products, priced $32 to $54, and 500 Sephora doors by April 2022 — one month after launch. That was The Outset, which announced it was winding down on 29 September 2026. The next day rhode opened in more than 500 Sephora doors across 19 European markets. rhode had ten products and no retail at all when e.l.f. Beauty paid $1 billion for it. Scarlett Johansson is the more famous woman. She got to the shelf first, too. The Outset opened in 500 Sephora doors in its second month. rhode sold nowhere but its own website for three years. What happened in the last week of September? The Outset's notice was short. It had decided to wind down operations, the brand said, after an incredible journey. Shopping closed. Orders already placed would still ship. Scarlett Johansson and Kate Foster Lengyel had started the brand in March 2022, which put it at four and a half years old when it stopped. rhode's announcement went the other direction entirely. Nineteen European markets at once — France, Germany, Italy, Spain, Poland, Sweden, Switzerland, Turkey and eleven more — across more than 500 Sephora doors and the retailer's own site, with two new ranges, Pocket Bronze and Highlight Milk, arriving alongside the core line. The two have nothing to do with each other. Retail rollouts get locked months ahead; wind-downs get decided in board rooms, not in response to a rival's press release. But the accident is useful, because it sets up a comparison nobody could have arranged on purpose. Two beauty brands, both started by famous women within three months of each other in 2022, both skincare-led, both built for an American shopper first. Same week, opposite ends of the industry. The Outset by Johansson Did the smaller name really beat the bigger one? Not in any sense a publicist would recognise. Johansson has twenty years of films behind her and an audience that predates Instagram. The Outset's own channels finished at roughly 438,000 followers on Instagram and about 610,000 on TikTok — a perfectly decent brand account, and nowhere near what its founder draws personally. The rest of the casualty list doesn't sort by fame either. Gwen Stefani's GXVE Beauty went in February 2026. Drew Barrymore's Flower Beauty went in September 2025, Kate Moss's Cosmoss three months before that, and Kate Hudson's InBloom belongs on the same list. Nobody here was short of recognition. So fame isn't the variable. Something else is doing the sorting. What did The Outset buy with its first cheque? Najafi Companies put in somewhere between $5 million and $10 million, with Beliade and Plus Capital alongside. The firm's founder said at the time that the point wasn't to bring another brand to market with a celebrity face on it. What the money bought was shelf space, a great deal of it, very fast. Five hundred Sephora doors in April 2022 is where most independent brands hope to arrive in year five. The Outset was there in month two, before anybody had bought the same product twice. That is not a prize you keep. Doors come with a number attached — sell-through per door per week — and the number gets reviewed on a schedule. Miss it and you lose facings, then shelves, then the account. The Outset grew from five products to around fourteen, came out of Sephora, and ended up scattered across Amazon, Nordstrom, QVC, Revolve, Goop, Credo and Cult Beauty. Third-party estimates put 2025 sales somewhere between $10 million and $25 million. Projections circulating at launch had put year one at $10 million. So: four and a half years of work, and the number had barely moved. Distribution is step three of four. The Outset started there; rhode spent three years on the two steps before it. What did rhode refuse to do for three years? One website. That was the whole distribution plan from 2022 until autumn 2025 — no Sephora, no Ulta, no Amazon, no wholesale of any kind, and ten products. Refusing retail is expensive. There's no store traffic to convert, so the brand has to manufacture its own demand every week, from nothing. What it buys in exchange is a customer list the brand owns outright and full gross margin with nobody taking a wholesale cut. It also buys something less obvious: no review date. rhode could spend as long as it liked working out which products people came back for, because nobody was going to pull its facings while it did. Retail arrived later, on rhode's terms. Sephora in the US and Canada in autumn 2025, the UK by year end, Europe in 2026. The company now calls rhode the top beauty brand at Sephora in North America and the UK. Same retailer, opposite order — and the order is the argument. rhode by Hailey Bieber What is ten products worth, and what is $350 million worth? e.l.f. Beauty agreed in May 2025 to pay $1 billion for rhode: $800 million at closing, up to $200 million more as a three-year earnout, funded with $600 million of committed debt and $200 million in newly issued shares. Behind that price sat $212 million of net sales over the prior twelve months, from ten products, sold direct. Now set Rare Beauty beside it. Launched September 2020 through Sephora. Revenue above $350 million a year. Bankers hired, $2 billion asked for. The process was reported on hold in September 2024, with buyers unwilling to pay a premium for a brand leaning on one celebrity and one product line. More revenue, smaller price. That isn't a comparison anyone makes out loud at a conference, but read the two deals together and the logic is hard to miss. What a buyer pays for is the share of the business that survives the founder going quiet. A billion dollars for $212 million of owned revenue. Two billion declined for more than $350 million routed through a retailer. Why did buyers stop paying for celebrity? Because of what a famous founder actually delivers, which is narrower than it looks from outside. Two things, reliably. A very loud first week, and a meeting with a retail buyer that other brands queue years for. Both land at the front, and neither builds on itself. Attention falls away from launch day unless something keeps feeding it, and the retail door, the moment it opens, stops being an asset and becomes a quota. Miss the quota and you're carrying the cost base of a company you never became. Which brings the Najafi line back around. The stated plan was not to stick a celebrity on a brand, and what came out was clean, vegan, allergen-free skincare for sensitive skin — a shelf several hundred other brands are already standing on. The face was unlike anyone else's. The serum wasn't. What does a four-year brand cost its manufacturer? None of these companies owns a factory. The products get developed and filled by contract manufacturers, a lot of them Korean ODM houses — the firms that build a formula for a client to put its own name on. The supplier carries the risk, and carries it first. A brand opening in 500 doors has to fill 500 doors, which makes that opening order the largest single PO anyone in the relationship will ever see. It lands before a single unit has sold through. The supplier is, in effect, lending working capital against a hypothesis. Whether a second order follows depends on a planogram review nobody from the factory attends, and nobody from the factory hears about it until the orders stop. And they stop quietly. There's no termination letter when a brand loses facings. There's a quarter where the forecast simply doesn't convert. Four brands in this bracket shut between June 2025 and September 2026. Read from Seoul, that isn't a story about celebrity culture. It's a receivables question, and the answers are the dull ones any concentrated-customer business already knows: MOQs written into the agreement, payment terms that don't quietly fund somebody else's launch, tooling and formulation billed up front rather than amortised across volume nobody has committed to. Is the celebrity brand model finished? Hardly, and the same week says so. rhode is a celebrity brand, and it just opened nineteen markets. Rare Beauty is a celebrity brand doing north of $350 million. What died is the lazy version of it — the one that treats a founder's name as a replacement for the work instead of a head start on it. The question a buyer asks now fits in a line: would this still sell if she stopped posting? rhode had an answer, in the form of ten products people reordered. The Outset never produced one. Half-price discounting in the weeks before the announcement is what not having an answer looks like on a price list. Rare Beauty by Selena Gomez Where does this leave the three parties? Manufacturers and ODM suppliers. The exposure is the opening order, not the founder. A brand that starts at full distribution buys big, buys early and can stop on no notice at all. Price the first PO as though it's the last one, because sometimes it is. Brands and the buyers who stock them. An invitation accepted too early converts a growth option into a quota. Settle before signing whether the brand can hold the space on its own pull, with the retailer's footfall taken out of the calculation. Investors. Revenue quality is being priced out loud now. Two hundred and twelve million dollars a brand owned outright was worth a billion. Three hundred and fifty million routed through somebody else's shelf wasn't worth two. Distribution doesn't make demand. It invoices for it.

Korea's customs service seized 117,000 counterfeit Korean-brand goods in 2025, and cosmetics were the single largest category at 41,903 items. Every one of those seizures happened at Korea's own border. The fake Beauty of Joseon sunscreen that prompted a new government council on 2 October 2026 was not entering Korea at all. It was listed on Amazon and TikTok Shop, where no Korean agency can order a removal. Korea seized 41,903 counterfeit cosmetic items at its own border in 2025. Its last full count of imitators operating abroad was taken in 2020. What did Korea actually launch on 2 October? The Council on K-Brand Intellectual Property Protection for Small and Medium Enterprises held its first meeting at the Daejeon Government Complex. Four bodies sit on it: the Ministry of SMEs and Startups, the Ministry of Intellectual Property, the Korea SMEs and Startups Agency and the Korea Intellectual Property Protection Agency. Its stated purpose is to connect two networks that have operated separately. On one side are 22 Global Business Centres — state-run trade offices that help Korean exporters enter a local market — spread across 14 countries including New York, Tokyo, Beijing, Hanoi and Jakarta. On the other are 10 overseas intellectual property centres covering 40 countries, among them Los Angeles, Beijing, Ho Chi Minh City and Mexico City. The commitments announced are information sharing on counterfeit and trademark cases, joint briefings and training, and a referral path by which a company that has received export support is passed on to intellectual property services. A memorandum of understanding between the agencies is planned rather than signed. The ministry's director general for global growth policy described counterfeiting as something that goes past lost sales to damage a brand's image and threaten a company's survival; the intellectual property side described the arrangement as a safety net built by joining export infrastructure to dispute response. No budget figure, no case-handling target and no agreement with any platform appears in the announcement. Why does a seal sticker matter more than a formula? The case the agencies put forward is a sunscreen sold under the Beauty of Joseon name, a brand owned by Goodai Global. Copies turned up on Amazon and TikTok Shop reproducing not only the outer carton but the seal sticker across the container opening. A second example involved Korean seaweed, where the copies matched the authentic product's price as well as its packaging. Both details describe the same shift. The seal and the price are the two checks a buyer can run at the moment of purchase without laboratory access. When a counterfeiter reproduces both, consumer-side verification stops working, and the burden of detection moves entirely to the rights holder and the platform. That is a different problem from the cheap knock-off that announces itself. It is also the reason the response has to be legal rather than chemical: there is nothing wrong with the copy that an inspection of the formula would reveal to a shopper. The Ministry of Food and Drug Safety What can Korean customs do that a trade office cannot? Korea already runs a counterfeit programme with statutory teeth, and it has scaled fast. On 23 January 2026 the Ministry of Food and Drug Safety opened a consultative body with the Ministry of Intellectual Property and the Korea Customs Service on the distribution of counterfeit cosmetics. On 12 May 2026 the same three agencies set out a joint inspection programme covering cosmetics bought through overseas online platforms: 110 inspections in 2024, 1,080 in 2025 and 1,200 planned for 2026, an elevenfold expansion in two years. The programme runs in four stages — information gathering, test purchase, laboratory testing and judgment, then enforcement. Enforcement means a customs hold so the goods do not enter domestic distribution, and the blocking of the selling page through the platform and the Korea Communications Standards Commission. Those are instruments a state can use because the goods and the viewers are inside its jurisdiction. A Global Business Centre has none of that. It can introduce a lawyer, fund part of a dispute and advise on where to file a trademark. It cannot hold a shipment it never sees or block a page served from a jurisdiction it does not govern. Twenty-two trade offices and ten IP centres connect a Korean exporter to legal help. The step that removes a listing belongs to the platform. Which direction is the revenue actually leaving in? Korean cosmetics exports reached $11.1 billion in the first nine months of 2026, up 31.1 percent year on year and equal to 97 percent of the entire 2025 total of $11.42 billion. Skincare alone accounted for $8.72 billion, up 45.1 percent. Shipments to the United States were $2.35 billion, up 40.6 percent. A counterfeit listing on a United States storefront removes revenue from a Korean exporter without any product crossing a Korean border in either direction. Korean customs never sees the consignment. The drug safety ministry has no authority over a product that is neither made nor sold in Korea. The communications commission can block a page for viewers in Korea and nowhere else. The entire enforcement stack is pointed at imports, and the exposure is in exports. How large is the outbound problem, and when was it last counted? The most recent comprehensive count is six years old. A 2020 survey by what was then the patent office identified 3,123 overseas businesses imitating Korean companies or products: 2,608 in China, or 83.5 percent of the total, followed by 103 in Mexico, 95 in India, 92 in Vietnam, 90 in the Philippines, 38 in the United Arab Emirates, 35 in Turkey, 23 in Malaysia, 20 in Thailand and 19 in Pakistan. No comparable survey was conducted in the five years that followed. A National Assembly member characterised that gap as a hole in the K-brand protection system. A replacement survey restarted in 2026 across ten countries, covering food, cosmetics, fashion and entertainment, and concludes in November 2026. The orders of magnitude in circulation come from elsewhere. An OECD estimate put counterfeit trade touching Korean intellectual property at roughly $9.69 billion as of 2021. A separate figure placing damage to K-beauty companies alone above 1 trillion won — about $740 million, converting at 1,350.60 won to the dollar, the rate on 2 October 2026 — comes from a lawmaker rather than an official statistical series, and should be read as an advocacy number. China took 46.7 percent of Korea's cosmetics exports in 2022. In the first nine months of 2026 it took 14.2 percent, while the United States share roughly doubled. Why is this the third interagency body in nine months? January, May and October 2026 each produced a counterfeit arrangement, and each had a different lead agency. The first two were led by the drug safety ministry and face inward, at goods arriving in Korea through direct overseas purchase. The October council is led by the SME ministry and the intellectual property ministry and faces outward, at Korean marks being copied abroad. That is a fair point in its favour: it addresses the direction the other two leave open, and it is the first of the three to do so. The sequence also reflects an institutional change. The patent office was elevated to full ministry status on 1 October 2025 and given an intellectual property dispute response bureau, upgraded from divisional rank, with the brief of coordinating national responses to disputes. The October council is that bureau being wired to another ministry's overseas offices a year later. What it brings is coordination. What it does not bring is a power that did not exist on 1 October 2025. What does a referral network give a brand that a takedown does not? It gives time, and only at the front end. Trademark squatting — registering someone else's brand name in a jurisdiction before the owner does, in order to sell it back or to block the owner's own imports — is defeated by filing first, and filing first is cheap. A brand routed from a trade office to an intellectual property centre before it ships is getting the one intervention that scales: a registration in the market where the goods will be sold. Once a counterfeit listing is live, the operative mechanism is the platform's own notice and takedown process, and neither Amazon nor TikTok Shop is a party to the council. Nothing in the announcement touches those processes, and nothing in it establishes a relationship with United States customs authorities or with a platform brand registry. A Korean brand filing a complaint against a fake listing on a United States storefront files it the same way after 2 October as before, with better odds of having a registered mark to file it on. What changes for a buyer running supply chain diligence? For an overseas distributor or retail buyer, the question a council does not answer is whether the brand in front of them owns its mark in the market where it will be sold. Where a Korean brand's trademark sits unregistered, a distributor can find its own imports blocked by a third party's registration, and the brand owner is in no position to indemnify. That turns registration status into a diligence item alongside manufacturing capacity and regulatory filings. The 40-country footprint of the intellectual property centres is a map of where state-funded help exists, not of where rights exist. Mexico City is on that list, and Mexico ranked second behind China in the 2020 imitator count — one of the places where the supply of assistance and the documented demand for it now overlap. Mexico City Where does this leave the three parties? For manufacturers and ODM suppliers — the original design manufacturers that develop and produce formulas for a client to sell under its own brand — a counterfeit is a development cost someone else avoided. The copy competes for the same shelf without having paid for the formula, and the contract manufacturer carries none of the brand risk. Their exposure runs through the brand owners who lose the volume. For brands and the buyers who stock them, the asset is the registration, not the council. Filing in a market before shipping to it is the only step in this system that happens early enough to change the outcome. For regulators and investors, the number to watch is the one Korea stopped collecting. A government that has run border seizures for years and a single census of overseas imitators in 2020 knows the scale of what arrives and not the scale of what is taken. The replacement survey closes in November. Until it reports, every figure in the policy is an inbound figure. Enforcement has an address. Korea's is at its own border.

At L'Oréal, the dermatological division grew 11.3% like-for-like in the first half of 2026 and the luxury division grew 5.4%. The division that grew fastest was neither: professional salon products, at 12.6%. Galderma's quickest segment over the same six months was prescription dermatology, at 67.9%. What is beating luxury beauty is not clinical formulation. It is the licensed professional standing between the product and the buyer. L'Oréal What do the two European majors actually report? L'Oréal's half-year accounts put group sales at €23.776 billion, up 6.8% like-for-like. Dermatological Beauty, the division holding CeraVe, La Roche-Posay and SkinCeuticals, reached €4,215.8 million on 11.3% like-for-like growth, 9.3% as reported. L'Oréal Luxe reached €7,996.7 million on 5.4% like-for-like, 4.4% as reported. Luxe remains close to twice the size of the dermatological division and is growing at roughly half the rate. Galderma's half-year release records net sales of $3.134 billion, up 24.6% at constant currency. Inside that, Injectable Aesthetics grew 12.1%, Dermatological Skincare — the segment holding Cetaphil and Alastin — grew 16.4%, and Therapeutic Dermatology grew 67.9%. Nemluvio, a prescription biologic, contributed $433 million and passed half of Therapeutic Dermatology sales for the first time. L'Oréal's fastest-growing division in the first half of 2026 was professional salon products at 12.6%, ahead of Dermatological Beauty at 11.3%. Which of these numbers travels with the wrong label? Three of them, and the errors all run the same direction. The 24.6% figure is frequently attached to Cetaphil. It belongs to Galderma as a whole: the company's total net sales growth at constant currency. Galderma does not disclose Cetaphil's sales separately at all. The brand sits inside Dermatological Skincare, and 16.4% is the closest verifiable number. The 9.3% and 4.4% pair for L'Oréal is the reported basis, which includes currency and perimeter effects. The like-for-like pair, 11.3% against 5.4%, is the one that measures underlying demand. Either comparison supports the point that derm is outgrowing luxury by roughly two to one, but mixing a reported figure for one division with a like-for-like figure for another produces a gap that does not exist. The third is the Estée Lauder skincare decline of 12%, which belongs to the fiscal year ended 30 June 2025, not the current one. Did luxury skincare actually fall? It fell, and then it stopped. In fiscal 2025 Estée Lauder's skin care net sales dropped 12% to $6,962 million on both a reported and organic basis, and the filing named declines from the Estée Lauder brand and La Mer alongside weakness in Asia travel retail and mainland China. In fiscal 2026, ended 30 June 2026, skin care rose 5% reported and 4% organic to $7,338 million, and the same filing now names La Mer as a contributor to growth rather than a drag on it. So the sharper framing is not that luxury skincare is collapsing. It is that luxury skincare spent a year recovering ground it had already lost, while the dermatological brands kept compounding from a higher base. Both can be true, and the second one is the structural fact. Estée Lauder's Why does the fastest division break the clinical thesis? Because it is not clinical. L'Oréal's Professional Products division, which sells through hair salons, grew 12.6% like-for-like — ahead of Dermatological Beauty's 11.3% and more than double Luxe. A salon colourist is not running a safety assessment or citing a study. What a colourist shares with a dermatologist is a licence, a chair and the authority to tell a customer what to buy. Galderma's own numbers point the same way from the other end. The segment compounding fastest there is prescription medicine, where the buyer does not choose the product at all. A physician does. Therapeutic Dermatology at 67.9% is not evidence that consumers prefer clinical skincare. It is evidence that the fastest-growing category in this industry currently sits outside consumer choice. So what is the premium actually attached to? To a third party with standing. For most of the modern history of prestige beauty, the thing that justified a price was held inside the brand: the heritage, the counter, the packaging, the house. That authority was self-issued and it worked for decades. What is displacing it is authority issued by someone else — a pharmacist who stocks the brand, a dermatologist who names it, a colourist who applies it, a prescriber who writes it. Read that way, the four L'Oréal divisions sort cleanly. The two growing above 11% both reach the customer through a professional. The two growing below 6% both reach the customer off a shelf. Formulation is not the variable doing the work. Distribution through a licensed intermediary is. Is GLP-1 the cause, or the story the sellers tell? The evidence that weight-loss medication is driving aesthetic demand is real and it is almost entirely commissioned by the companies selling the remedy. Galderma's own research, published alongside an international Delphi consensus on managing aesthetic needs in rapid medication-driven weight loss, reports that 62% of GLP-1 users received an aesthetic treatment after a clinician recommended one, and that 48% noticed significant facial changes. A separate survey of 400 clinicians presented at a dermatologic surgery meeting in November 2025 found 81% using hyaluronic acid fillers for GLP-1-related concerns, with the average number of GLP-1 patients per provider rising from 95 in 2023 to 225 in 2024. That survey was run by Allergan Aesthetics, which sells the fillers. None of this makes the effect imaginary. Both datasets describe the same mechanism from the inside of an industry that profits from it, which is a reason to treat the direction as established and the magnitude as unsettled. The more durable observation underneath the GLP-1 story is simply that a clinician entered the purchase decision, which is the same shift the division numbers show. Korean pharmaceutical groups own consumer skincare brands, Olive Young built them a retail category, and Korean firms supply the injectables the clinical boom runs on. Where does Korea sit in this? On both sides of it, which is unusual. Korean pharmaceutical companies have spent a decade building consumer skincare brands rather than licensing their names to one: Dongkook Pharmaceutical owns Centellian24, Daewoong owns Easydew, Dong-A owns Fation, Dongwha owns Fusidyne and Hanmi Science owns Adesii. Dongkook reported first-quarter 2026 revenue of 251.0 billion won, about $185 million at 1,357 won to the dollar on 1 October 2026, up 12.2%, with Centellian24 exports up 332% against the same quarter a year earlier. Cumulative Centellian24 sales from 2015 to 2024 reached 1 trillion won, roughly $737 million. Olive Young then did something no Western retailer has an equivalent for: it turned the pharmaceutical origin into a named shelf. Advanced Derma launched in March 2026 as a category co-developed with domestic pharmaceutical companies, reached 650 stores by early August, and recorded June sales more than 260% above April. Around 70% of its buyers are foreign. A category built on Korean clinical credibility is being bought largely by people who do not live in Korea. Who supplies the clinical boom itself? Korean manufacturers, to a degree the Western division reports do not show. Hugel recorded first-half 2026 revenue of 254.5 billion won, about $188 million, with botulinum toxin revenue of 149.4 billion won, roughly $110 million, up 46.6%, and toxin sales in the Americas more than doubling. PharmaResearch recorded second-quarter exports of 84 billion won, about $62 million, up 62% and amounting to 47% of its revenue, with cosmetics exports alone up 124%. So when a European group reports that injectable aesthetics grew 12.1% and attributes part of it to medication-driven weight loss, a share of the volume behind that demand originates in Korean plants. The clinical premium is being captured in Western income statements and manufactured, in part, somewhere else. That is the same structure K-beauty has run in colour and skincare for twenty years, arriving now in a category with a prescription attached. Where does this leave the three sides? For manufacturers and ODM partners — the contract developers that design and produce under other companies' brand names — the valuable capability is shifting from speed of launch to evidence a professional will repeat. A formula that a pharmacist can defend is worth more than a formula that trends. For brands and the buyers who source them, the question at a sourcing meeting changes from what the range looks like to who signs off on it, and the answer is a document rather than a mood board. For regulators and investors, the boundary between cosmetics and medicine is where the growth now sits, and it is a boundary with two different rulebooks, two different liability regimes and two different approval clocks on either side of it. Luxury beauty did not lose to better chemistry. It lost the exclusive right to say what works. The companies growing fastest are the ones that borrowed that right from someone licensed to hold it.

South Korea licenses cosmetic claims. Eleven categories are written into the enforcement rule of its Cosmetics Act, and wrinkle improvement, skin whitening and UV protection are three of them; 524 functional-cosmetic filings cleared in the first half of 2023, 89 percent of them domestic. The United States pre-approves no cosmetic product or ingredient at all, colour additives aside. The same sentence is a state-issued permit in Seoul and a change of legal category in the United States. Korea recognises eleven licensed claim categories. The United States pre-approves no cosmetic at all. What does a claim do to a product's legal category? The Federal Food, Drug, and Cosmetic Act defines a cosmetic at section 201(i) as an article applied to the body for cleansing, beautifying, promoting attractiveness or altering the appearance. It defines a drug at section 201(g)(1) as an article intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease, or intended to affect the structure or any function of the body. Nothing in either definition refers to what is in the jar. Both turn on intended use. Intended use is established from the label, the packaging, the website, advertising and promotional material, from why consumers buy the product and what they expect it to do, and from ingredients with a well-known therapeutic reputation. A product can satisfy both definitions at once, and a great many do: anti-dandruff shampoo, fluoride toothpaste, antiperspirant deodorant and any moisturiser carrying an SPF number are each a cosmetic and a drug simultaneously, and have to meet both sets of requirements. The consequence follows mechanically. A cosmetic that claims to affect the structure or function of the body is a drug. A drug marketed without an approved application is an unapproved new drug under section 505(a). At no point in that sequence does anyone examine the formulation. Why is the same claim ordinary business in Korea? Korea built a licensing route for exactly the claims the American definition treats as drug claims. The eleven functional-cosmetic categories cover prevention of melanin formation, lightening of existing pigmentation, skin elasticity and wrinkle improvement, tanning and UV protection, UV blocking and scattering, hair colouring, hair removal, relief of hair-loss symptoms, relief for acne-prone skin in rinse-off products, skin barrier restoration for itch relief, and reduction in the appearance of stretch marks. Two routes lead into that list. A full evaluation at the National Institute of Food and Drug Safety Evaluation applies to novel ingredients or non-standard formulations and requires a safety and efficacy dossier. A simplified report applies where a product uses ministry-notified ingredients at specified concentrations, or matches a product already approved for the same manufacturer. Either way the claim ends up certified by the state before the product ships. The volume is the point. Of the single-efficacy filings cleared in the first half of 2023, UV filters accounted for 52.5 percent, hair-loss relief for 19.7 percent, hair dye for 7.9 percent, acne relief for 6.6 percent, whitening for 5.5 percent and wrinkle improvement for 4.4 percent. Ninety-two more products cleared carrying all three of whitening, wrinkle improvement and UV protection at once. Stacking certified claims is a normal competitive move in the domestic market, not an act of marketing excess. The claim establishes intended use, and intended use establishes the category. The formula is never examined. What does the United States offer in place of that licence? Nothing equivalent. The Food and Drug Administration does not pre-approve cosmetic products or ingredients, with the narrow exception of some colour additives. There is no American filing that converts a wrinkle claim into a cleared claim, because there is no American category between cosmetic and drug for it to land in. The Modernization of Cosmetics Regulation Act does not create one. It requires facilities to register with the FDA, renew every two years and update within 60 days of a change; it requires a responsible person to list each marketed product with its ingredients and update annually; it requires adequate substantiation of safety, with records to support it; and it adds adverse event reporting and new labelling rules covering fragrance allergens and asbestos testing in talc. Efficacy is absent from that list. Registration under this regime is a filing, not a clearance. That distinction is worth stating plainly because the registration numbers are read as progress. Korean facilities registered with the FDA reached 947 by the end of June 2026, up from 617 in January of the previous year, a rise of 53.5 percent. None of those 947 registrations approves a single claim. Authority over the claims themselves is split: the FDA decides what the product legally is and governs its labelling, and the Federal Trade Commission polices whether the advertising is truthful, not misleading and adequately supported. Which sentences has the agency actually objected to? The record is specific rather than abstract. Language the FDA has cited in warning letters to cosmetic sellers includes enhancing the production of elastin and collagen in the skin, supporting the synthesis of new skin fibres and boosting cell regeneration, reducing the depth of wrinkles by attenuating muscle contraction, repairing the DNA of the skin, and healing damaged skin from scars and burns. Avon and Lancome received letters of this kind in 2012, and smaller sellers have received them steadily since. The enforcement continues under current law. A warning letter dated 2 April 2026 to a Michigan contract manufacturer addressed products marketed for shingles and for genital herpes relief, citing sections 501(a)(2)(A) and 501(a)(2)(B) for adulteration, sections 301(d) and 505(a) for unapproved new drugs, and the current good manufacturing practice regulations at 21 CFR parts 210 and 211. The firm was directed to identify discontinued drugs by national drug code, engage a qualified consultant for manufacturing compliance, and respond within 15 working days. One tool did disappear. Import Alert 66-38, covering skin care products labelled as anti-aging creams, operated for roughly three decades and was withdrawn in late 2017. Withdrawing a detention instrument changed nothing about the statutory definition it had been enforcing. Does Korea let overclaiming pass at home? It does not, and assuming otherwise gets the comparison backwards. Article 13 of the Cosmetics Act prohibits labelling or advertising that leads consumers to mistake a cosmetic for a drug, that presents a non-functional cosmetic as a functional one, or that departs from the safety and efficacy review result. Article 14 requires a company to be able to substantiate factual claims and to produce the evidence within 15 days of a ministry request. Enforcement runs at scale. Between January 2021 and September 2025 the drug safety ministry identified 12,617 instances of improper cosmetic advertising, and 8,727 of them — roughly 70 percent — involved language creating confusion with medicines, such as skin regeneration, inflammation relief and acne improvement. Between 13 March and 15 April 2026 ten companies were penalised, with advertising or sales suspensions running from 15 days to four months, and three manufacturing registrations cancelled outright. So the difference between the two markets is not vigilance. It is what the violation does to the product. In Korea the advertisement is punished and the product remains a cosmetic on the shelf. In the United States the product stops being a cosmetic, and a consignment of goods that are legally unapproved new drugs does not enter. Bemotrizinol clears a Korean review in four to six months. The American pathway runs to roughly $18 million and more than a decade. What does sunscreen show that nothing else does? Sunscreen is the clean case, because the product is identical and only the classification moves. Korea treats UV protection as a functional cosmetic, and UV filters made up more than half of all single-efficacy filings cleared in the first half of 2023. The United States treats sunscreen as an over-the-counter drug, which brings with it monograph compliance, a Drug Facts panel and drug establishment registration. The ingredient list moves with the classification. A University of Miami law review analysis of the pathway for bemotrizinol, a UV filter long available outside the United States, put the American route at roughly $18 million and more than ten years of safety testing, followed by two to three years of FDA review and a 45-day comment period. The same analysis put the Korean route at four to six months once clinical data is submitted, with a 60-day comment period. The FDA has approved no new UV filter since 1999. A Korean sunscreen does not fail in the United States because it performs badly. It fails because the filter that gives it its texture has no American monograph, and because the sentence describing what it does moves it into a category with a ten-year queue. What happens when that question is put directly? I once sat down with a manufacturing team whose formulation capability was, by any measure, world-class. Their launch deck was another matter. Skimming it, you would have concluded they were selling a fountain of youth. Before raising a single ingredient, I asked the question the whole document turned on: did they intend to launch the line overseas as an OTC drug? There was a long pause. They did not, not at that stage — which I had already assumed, because neither the budget nor the international compliance function was there. My reply was that almost everything written in the deck therefore had to go. None of that exchange concerned the quality of the formulation, which was never in doubt. It concerned which of two regulatory objects the document had just described. Domestic selling absorbs a stretched claim, because a pitch can be qualified in the room and a certificate can be produced on request. Export does not work that way. A buyer gives a label a second of attention on a shelf or a screen, and a customs officer gives it less. The claim has to survive alone. Inside the bustling beauty brand laboratory, where innovative product formulations are developed and assessed for international appeal. Where does the cost of a rewritten claim actually land? A deck built for the domestic licence has to be dismantled before it travels, and the dismantling is not a copywriting exercise. Removing the claim is the cheap outcome. Keeping it means the drug pathway: establishment registration, a national drug code, a Drug Facts panel in place of the marketing panel, and manufacturing under 21 CFR parts 210 and 211, with the documentation burden that carries. For a manufacturer whose compliance function was built to file functional-cosmetic reports with one ministry, that is not a budget line. It is a different company. The border keeps the score. American refusals of Korean cosmetics reached 171 product lines in fiscal 2026, against 158 across the whole of fiscal 2025, in the same period that registered Korean facilities rose 53.5 percent. Registrations and refusals are rising together, which is what happens when entry volume grows faster than the compliance function behind it. Why do strong technical teams write the deck this way? The habit is structural, not a failure of judgement. In a market where the state certifies eleven claim categories, claim strength is a legitimate axis of competition and a formulation team can win on it directly. A triple-efficacy certificate is evidence of laboratory work, obtained through a filing, defensible against a regulator. Ninety-two products cleared on that basis in a single half-year. Export strips out the certificate and leaves the habit intact. The deck still reads as a list of proven functions, because in the market it was written for, the functions were proven — to the satisfaction of the only authority that was asked. The document that made the product credible at home is the document that reclassifies it abroad. This is why claim review belongs before formulation review in any export assessment, and why a supplier's launch deck is diligence material rather than marketing collateral. The deck states, in the supplier's own words, which regulatory regime they have been operating in. Inside the bustling beauty brand laboratory, where innovative product formulations are developed and assessed for international appeal. What does this look like from three sides? For manufacturers, formulation capability and claim capability are licensed separately, and only one of them crosses a border. Engineering depth transfers intact; the certificate that made the engineering sayable does not. A firm that can build the formula and cannot fund the drug pathway has a real product and no legal sentence to sell it with. For brands and buyers, a Korean functional-cosmetic certificate is a Korean clearance and nothing else. A supplier presenting one as evidence of export readiness has disclosed something useful about their regulatory function, and the disclosure is free. Reading the claims before reading the ingredient list reverses the usual order of diligence and catches the expensive problem first. For regulators and investors, 947 registered facilities counts filings, not cleared products, and the refusal line has risen alongside it. A registration figure describes how many Korean plants have told the FDA they exist. It describes nothing about how many of their products can legally say what their labels say. The formula crosses the border. The claim does not.

Musinsa opened a 1,262-square-metre beauty store in Hongdae, Seoul on 11 September 2026, four days after filing for a listing on the main Korean bourse. The reading that followed was that Olive Young's grip on K-beauty distribution had loosened. Olive Young's own half-year numbers point the other way: its share of Korean beauty retail reached 21.5% in the first half of 2026, up from 18.8% a year earlier and the highest it has recorded. The second gateway opened while the first one widened. Musinsa's Hongdae floor is about a third larger than Olive Young's, on a base of one store against 1,376. What did Musinsa actually open in Hongdae? The store occupies 1,262 square metres, reported locally as roughly 400 pyeong (14,233 sq ft) — the Korean floor-area unit of about 3.3 square metres — across four levels from the basement to the third floor. Musinsa had sold cosmetics before this, inside its Musinsa Standard apparel stores and at the Megastore it opened in Seongsu in April 2026. Hongdae is the first address it has given over entirely to beauty. Two more standalone locations, in Seongsu and on Jeju, are scheduled for November. The assortment runs to about 870 brands and 12,000 products. Of the roughly 600 beauty brands on the main selling floors, the company puts about 70% in the indie category — labels with little or no existing offline distribution. The second floor carries skincare, hair, body, men's and dental care; the first carries colour cosmetics and fragrance; the third holds a café and an outdoor terrace rather than more shelf. The basement is the unusual part. A licensed pharmacy occupies 176 square metres, stocking about 270 brands and 2,000 products, roughly 90% of them beauty. It is run as a separate business by the pharmacy franchisee, on its own point-of-sale system. Musinsa shapes what is curated there and does not set price, stock or transaction terms. Two or more pharmacists consult on acne and on scalp and hair care, and fill prescriptions. Musinsa Beauty Hongdae Flagship Store, ⓒinhoocho.com Did Olive Young's position weaken while this happened? It strengthened. Olive Young's first-half 2026 revenue was 2.9433 trillion won (about $2.17 billion), measured against a domestic beauty market, online and offline combined, of 13.7162 trillion won (about $10.1 billion). That is the 21.5% figure. Won amounts in this article are converted at 1,358 won to the dollar, the Seoul close on 23 September 2026. The series behind that number matters more than the number. The same share was 12.2% in 2022, 14.9% in 2023, 17.0% in 2024 and 18.8% in the first half of 2025. Full-year 2025 revenue was 5.83 trillion won (about $4.29 billion) across more than 1,370 stores. Every year that new challengers were announced, the incumbent took a larger slice. The challenger arrived in the middle of the incumbent's best half. Olive Young's share of Korean beauty retail was 12.2% in 2022. In the first half of 2026 it was 21.5%. Why does a 21.5% share still work like a gateway? Because a share of spending is not the same thing as control of discovery. Four fifths of Korean beauty money is spent somewhere other than Olive Young. What Olive Young holds is the shelf a new brand has to reach to become visible at national scale, and the door most inbound shoppers walk through first. Korea's competition regulator examined exactly this in December 2023. Its decision recorded that Olive Young held over 70% of the physical health-and-beauty retail market — the drugstore-style format that sells cosmetics alongside supplements and personal care. It nonetheless declined to designate the company as market-dominant, reasoning that online channels and the newer cosmetics retail formats belong inside the relevant market. It fined the company 1.896 billion won (about $1.4 million), issued a corrective order, and made a criminal referral over conduct requiring suppliers to hold promotions exclusively with it. That decision is the frame for everything that has happened since. The regulator's answer to gatekeeping was that channel entry would discipline it. The Hongdae store is the test. What does admission to that gateway cost? Reported fee schedules circulated in January 2026 put the base selling commission on offline cosmetics at 40%. On top of that sit a sales promotion charge of 4.75%, a sales incentive of 6.94% and an information-provision fee of 2.95% to 3.05%. The stack comes to about 54.74% of a brand's sales before the product itself has been paid for. Online, the base commission is 29.36% and the all-in figure runs above 44%. Brands that reach the shelf through a vendor intermediary add a further 10% to 15%. A separate account of the same terms puts the total in the low-to-mid 50s, built from a selling commission of 35% to 45% plus logistics and display charges. The two accounts disagree on the components and agree on the magnitude. Brand-side descriptions of the result are consistent: once production cost and commission are deducted, and once overlapping discount events add their own charges, the margin is thin to absent. This is the number that makes the word gateway literal. A toll of that size is payable only by brands that have already found demand somewhere cheaper. Fees take 54.7 won of every 100 won a brand sells on the offline shelf, before the product is paid for. How does a floor of inexpensive products pay for 400 pyeong (14,233.3 sq. ft)? Musinsa reported 250 million won (about $184,000) in sales over the store's first three days, on an average transaction of roughly 110,000 won (about $81). A large share of the assortment is priced under 20,000 won (about $15). Those two figures only reconcile one way: the average shopper is leaving with six items or more. That is the arithmetic of a discovery floor rather than a destination floor. It does not monetise through the price of any single product. It monetises through how many unfamiliar things a shopper is willing to pick up in one visit, which is a function of how easy the floor is to wander. The layout reflects that — wide circulation, long sightlines, and a third floor given to a café and terrace instead of additional shelf. Openness is not decoration in this format. It is the revenue mechanism. The opening-week buyer profile fits the same design. Women accounted for 76% of purchases, and more than 80% of those women were in their twenties or thirties. A sub-20,000-won price architecture aimed at a younger shopper is a different business from a 110,000-won basket built out of two premium items. Musinsa Beauty Hongdae Flagship Store, ⓒinhoocho.com Why is haircare where the two formats diverge most? Olive Young's floors are organised around skincare and colour, the two categories where Korean brands have the deepest bench and the incumbent has the most entrenched planograms. Musinsa's second floor gives hair, scalp and body their own run of the store, with testers that extend to styling appliances a shopper can switch on rather than sealed boxes. The basement pharmacy consults on scalp and hair alongside acne. The category logic is skinification — applying skincare actives and skincare routines to hair and scalp, so that a shampoo is merchandised on its ingredient list rather than its fragrance. It is the part of Korean beauty where the incumbent has the least shelf to defend, because the established hair brands are largely multinational and the Korean entrants are recent. A challenger with 400 pyeong (14,233 sq ft) and 600 brands can build a category position there that it cannot build in cushion foundation. Who is the foreign shopper actually buying from? Foreign customers were 2% of Olive Young's offline sales in 2022. In August 2026 they were 33%. Foreign shoppers made 11.01 million transactions at its Korean stores between January and August 2026, spending more than 1 trillion won (about $736 million), up 47% on the same period a year earlier. Hongdae is where that flow is densest: about 67% of foot traffic in the district comes from outside the country. Shinsegae's Chicor store there took 91% of its April 2026 revenue from foreign visitors. Musinsa's foreign share reached about 60% by its first Sunday, at a conversion rate roughly double its other offline locations, with overseas shoppers concentrating on derma and functional skincare while domestic shoppers bought colour. Every operator in the district is competing for the same inbound flow within a few hundred metres. Olive Young's Hongdae store, opened in 2024, runs to about 300 pyeong (10,675 sq ft) across three floors. Chicor's, opened in December 2025, runs to about 150 pyeong (5,338 sq ft) with roughly 230 brands. Musinsa's is the largest of the three. Musinsa Beauty Hongdae Flagship Store, ⓒinhoocho.com What is Musinsa bringing that cannot be copied quickly? A customer file. Musinsa counts 16.4 million fashion customers, and 83.1% of first-time beauty buyers on the platform between January and August 2026 were people who already shopped it for clothing. Its beauty brand count went from about 800 in 2021 to roughly 2,500 by August 2026, and beauty transaction volume rose 1,340% between 2021 and 2025. Acquisition cost for a beauty customer is close to zero when the customer is already logged in. The listing filing sets the frame. Musinsa filed with the Korea Exchange securities market division on 7 September 2026, targeting a listing in the first half of 2027. The filing describes the review as testing the feasibility of a listing as a funding option, not as a committed offering. Market estimates of the valuation run from 8 trillion to 10 trillion won (about $5.9 billion to $7.4 billion); those are the market's numbers rather than the company's. Consolidated first-half 2026 revenue was 821.7 billion won (about $605 million), up 22.5%, with export sales of about 37.2 billion won (about $27 million), more than nine times a year earlier. Full-year 2025 revenue was 1.47 trillion won (about $1.08 billion), a quarter of Olive Young's. Beauty is the part of that story that carries the multiple. A fashion platform listing at a fashion platform's earnings ratio does not reach 10 trillion won ($7.4 billion). Musinsa Beauty Hongdae Flagship Store, ⓒinhoocho.com How many gateways is the market actually opening? More than two. Shinsegae's Chicor runs 21 stores and has set a target of 40 by 2028. Daiso has taken its beauty brand count from seven to 170 in four years, entirely at price points of 5,000 won (about $3.70) or below, with beauty sales up 70% in 2025 after 144% in 2024, and opened its first beauty-dedicated store near Konkuk University. Off Beauty has reached 45 stores since 2024. Hyundai's Coasis has four locations with a fifth planned. Kurly Beauty carries around 1,000 brands online, and Coupang runs a separate luxury beauty platform. Olive Young's own expansion is sideways rather than defensive. Olive Better, its wellness format, opened in Gwanghwamun in January 2026 and in Gangnam, took a 93-pyeong (3,309 sq ft) position inside a 233-pyeong (8,291 sq ft) complex store at Starfield Anseong on 30 August, and carries a target of 10 locations by the end of 2026. Foreign customers were 7% of the Gwanghwamun store's sales in early February and close to 50% by late April. The incumbent is not fighting for the beauty shelf it already holds. It is annexing the adjacent one. Musinsa Beauty Hongdae Flagship Store, ⓒinhoocho.com Where does each side of the table stand now? For manufacturers and ODM suppliers — the contract developers and manufacturers that formulate and produce for brands that own no factory — more gateways means more brands, more SKUs and shorter production runs. The economics of that are mixed. Order counts rise while order sizes fall, and the fixed cost of a compliant formulation does not fall with them. For brands and the buyers who source them, the change is that shelf has become a negotiated cost rather than a fixed toll. A 54.7% fee stack is defensible when it is the only route to national visibility and harder to defend when a second physical route exists at 400 pyeong (14,233 sq ft) with 600 brands on it. One store is not yet leverage. Three, with a listed balance sheet behind them, is the beginning of leverage. For regulators and investors the sequence is the uncomfortable part. The 2023 decision declined to call Olive Young dominant on the reasoning that channel entry would discipline it. Channel entry arrived, and the incumbent's share went from 14.9% to 21.5%. Anyone underwriting Musinsa at 10 trillion won ($7.4 billion) is underwriting the proposition that the next three years break that pattern. Korea's beauty retail map now has a second gateway. It does not yet have a second gatekeeper.